Piper Sandler raised the firm’s price target on Humacyte to $4 from $3 and keeps a Neutral rating on the shares after assuming coverage of the name. The firm views Humacyte as one of the premier players in the regenerative medicine space, having developed innovative off-the-shelf and universally-implantable human acellular vessel technology, but doesn’t love the stock setup heading into the initial HAV launch in vascular trauma in September, Piper says. The firm thinks more visibility on the launch is necessary for the stock to work, and views shares as fairly valued.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HUMA:
- Humacyte Announces Public Offering and Expected Proceeds
- Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
- Humacyte 13.4M share Spot Secondary priced at $3.00
- Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
- Humacyte, Inc. Announces Proposed Public Offering of Common Stock
